| Recurrence-free survival | Cancer-specific survival | Overall survival | ||||||
---|---|---|---|---|---|---|---|---|---|
 | HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | P value |
Age (years) | |||||||||
 Body mass index (kg/m2) | 1.04 | 0.90–1.19 | 0.621 | 1.03 | 0.89–1.20 | 0.680 |  |  |  |
Serum creatinine (μmol/l) | |||||||||
 Tumor stage (IIA2 vs. IB2) | |||||||||
  Histology (non-squamous vs. squamous) | 1.28 | 0.70–2.35 | 0.427 | 1.30 | 0.68–2.47 | 0.430 | 1.28 | 0.51–3.21 | 0.602 |
  Tumor differentiation (G3 vs. G1–2) |  |  |  | 4.16 | 1.93–8.97 | <0.0001 |  |  |  |
  Deep stromal invasion (yes vs. no) | 0.77 | 0.40–1.49 | 0.433 | 0.83 | 0.42–1.63 | 0.586 | 1.21 | 0.68–2.16 | 0.516 |
  LVSI (yes vs. no) | 1.26 | 0.73–2.15 | 0.405 | 1.16 | 0.66–2.04 | 0.616 | 0.91 | 0.56–1.48 | 0.708 |
  Positive margins (yes vs. no) | 3.70 | 1.86–7.35 | <0.0001 | 4.42 | 2.15–9.08 | <0.0001 | 3.26 | 1.69–6.28 | <0.0001 |
  Positive nodes (yes vs. no) | 5.21 | 2.82–9.62 | <0.0001 | 6.67 | 3.47–12.80 | <0.0001 | 3.47 | 2.09–5.78 | <0.0001 |
  Positive parametrium (yes vs. no) | 3.37 | 1.67–6.82 | 0.001 | 3.14 | 1.54–6.41 | 0.002 | 2.84 | 1.41–5.73 | 0.004 |
Diabetes | |||||||||
 No | Reference | Reference | Reference | Reference | Reference | Reference | Reference | Reference | Reference |
 HbA1c < 7% | 1.49 | 0.69–3.22 | 0.307 | 1.57 | 0.68–3.62 | 0.290 | 2.06 | 1.04–4.07 | 0.039 |
 HbA1c ≥ 7% | 3.33 | 1.89–5.88 | <0.0001 | 3.60 | 1.96–6.61 | <0.0001 | 4.35 | 2.64–7.17 | <0.0001 |
Hypertension (yes vs. no) | |||||||||
 Cardiovascular disease (yes vs. no) |  |  |  | 0.57 | 0.22–1.48 | 0.245 |  |  |  |
 Metformin (yes vs. no) |  |  |  |  |  |  | 1.13 | 0.41–3.11 | 0.807 |
 Complete response (yes vs. no) | 0.58 | 0.36–0.95 | 0.031 | 0.52 | 0.31–0.87 | 0.013 | 0.78 | 0.50–1.22 | 0.279 |